Hewitt, Richard J. http://orcid.org/0000-0003-4294-0052
Puttur, Franz
Gaboriau, David C. A. http://orcid.org/0000-0003-4047-6487
Fercoq, Frédéric http://orcid.org/0000-0002-4825-024X
Fresquet, Maryline
Traves, William J.
Yates, Laura L.
Walker, Simone A.
Molyneaux, Philip L. http://orcid.org/0000-0003-1301-8800
Kemp, Samuel V. http://orcid.org/0000-0002-6639-0166
Nicholson, Andrew G.
Rice, Alexandra
Roberts, Edward http://orcid.org/0000-0002-8229-1715
Lennon, Rachel http://orcid.org/0000-0001-6400-0227
Carlin, Leo M. http://orcid.org/0000-0001-7172-5234
Byrne, Adam J.
Maher, Toby M.
Lloyd, Clare M. http://orcid.org/0000-0001-8977-6726
Funding for this research was provided by:
Wellcome Trust (107059/Z/15/Z)
Imperial College London (Imperial College Faculty of Medicine Clinician-Investigator Scholarship Award)
Article History
Received: 3 December 2022
Accepted: 11 September 2023
First Online: 27 September 2023
Competing interests
: R.J.H. received, unrelated to the submitted work, consultancy fees from Boehringer Ingelheim. P.L.M. received, unrelated to the submitted work, industry-academic funding from AstraZeneca via his institution and speaker and consultancy fees from Boehringer Ingelheim Trevi and Hoffman-La Roche. A.J.B. received, unrelated to the submitted work, consultancy fees and/or industry/academic funding from Ammax, Devpro, and Ionis pharmaceuticals, via his institution. A.G.N. is or has been a scientific advisor relating to IPF trials for Medical Quantitative Image Analysis, Galapagos, Boehringer Ingelheim and Roche, as well as receiving payment for educational activities relating to interstitial lung disease from Boehringer Ingelheim and UpToDate. T.M.M. received, unrelated to the submitted work, consultancy fees in relation to pulmonary fibrosis from Abbvie, Agomab, Apellis, Astra Zeneca, Bayer, Biogen Idec, Blade Therapeutics, BMS, Boehringer Ingelheim, Bridge Therapeutics, Carthronix, Chieisi, CohBar, CSLBehring, Daewoong, Daiatchi, DevPro, Endeavor, Fibrogen, Galapagos, Galecto, GlaxoSmithKline, Insilico, IQVIA, Kinevent, Pliant, Pfizer, Puretech, Qureight, Redx, Remedy Cell, Respivant Sciences, Roche, Shinogi, Surrozen, Theravance, Three Lakes Partners, Trevi, UCB, United Therapeutics, Veracyte, Vicore. The remaining authors declare no competing interests.